Diffuse and limited cutaneous systemic scleroderma.

Abstract

Juvenile systemic scleroderma (jSSc) is a rare disease. Based on the first large data collection on this patient group, the disease course was demonstrated to differ from that in adults. The concept of persistence of maternal cells in patients with SSc remains pathogenetically fascinating, as does the resemblance with graft-versus-host-disease. In view of new therapeutic options, controlled trials have not established a gold standard for treatment, but autologous bone marrow transplantation may be considered a rescue therapy for selected patients. Palliative therapies have also improved markedly in recent years. The first controlled trials for patients with jSSc are being proposed.

• Authors: I Foeldvari
• Journal: Current opinion in rheumatology (Curr Opin Rheumatol) Vol. 12 Issue 5 Pg. 435-8 (Sep 2000) ISSN: 1040-8711 [Print] United States
• PMID: 10990182 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents
• Immunosuppressive Agents
• Steroids
• Thalidomide

Topics

• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Child
• Child, Preschool
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Immunosuppressive Agents (therapeutic use)
• Maternal-Fetal Exchange
• Palliative Care
• Pregnancy
• Prognosis
• Scleroderma, Systemic (blood, complications, diagnosis, therapy)
• Severity of Illness Index
• Steroids
• Thalidomide (therapeutic use)